SEC Company Response from C4 Therapeutics, (CCCC) — Dec 8, 2025
C4 Therapeutics, Inc.
Date: Dec. 8, 2025 · CIK: 0001662579 · Accession: 0001628280-25-055804
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291696
Letter
Document December 8, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Mr. Tyler Howes Re: C4 Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-291696 Acceleration Request Requested Date: December 10, 2025 Requested Time: 4:05 p.m., Eastern Time Dear Mr. Howes: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), C4 Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to December 10, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin O'Connor at (212) 813 8853. If you have any questions regarding this request, please contact Edwin O'Connor of Goodwin Procter LLP at (212) 813 8853. Sincerely, C4 THERAPEUTICS, INC. /s/ Andrew J. Hirsch . Andrew J. Hirsch. President and Chief Executive Officer cc: Jolie M. Siegel, C4 Therapeutics, Inc. Edwin O’Connor, Esq., Goodwin Procter LLP
Show Raw Text
CORRESP 1 filename1.htm Document December 8, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Mr. Tyler Howes Re: C4 Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-291696 Acceleration Request Requested Date: December 10, 2025 Requested Time: 4:05 p.m., Eastern Time Dear Mr. Howes: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), C4 Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to December 10, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Edwin O'Connor at (212) 813 8853. If you have any questions regarding this request, please contact Edwin O'Connor of Goodwin Procter LLP at (212) 813 8853. Sincerely, C4 THERAPEUTICS, INC. /s/ Andrew J. Hirsch . Andrew J. Hirsch. President and Chief Executive Officer cc: Jolie M. Siegel, C4 Therapeutics, Inc. Edwin O’Connor, Esq., Goodwin Procter LLP